Log inTry free

Damora Therapeutics (DMRA) stock

Market cap $1.3B

$20.66
+1.92%

Prices 20 minutes old, as of 9:14 AM ET. Members see real-⁠time prices.

Quality Score
2
Below Average
In its industry
#91of 260
Biotech
Cash$541M in cash. One of the last four quarters brought cash in while the others used it.On Jun 30 · the company says “into 2029”

Follow DMRA's news. Members get an alert when Damora Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when DMRA files newsNo sign-up. No card. One tap and you're in.
Cash$541M in cash. One of the last four quarters brought cash in while the others used it.On Jun 30 · the company says “into 2029”
Pipeline and cash

What's next for DMRA, and how long its cash lasts

From Damora Therapeutics’s SEC filings and ClinicalTrials.gov: the company’s own words and the arithmetic, not a forecast. Companies often miss their own dates.

Cash runway to Jun 30

$541M in cash

One of the last four quarters brought cash in while the others used it, so an average says little about the next.

What it means: a runway is counted only when each of the last four quarters used cash. The company's own estimate, which counts its plans, is “into 2029” (8-K, Jan 12).

For members: the share count, 1 raise, 2 shelf filings, and the math.

Jennifer JarrettPresident and Chief Executive OfficerFrom their own Form 4 filings

For members: their 3 filings and quotes, and an alert each time they file.

Get an alert when DMRA files newsNo sign-up. No card. One tap and you're in.
Biotech dates

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first.

65 more companies with an FDA date or a trial due in these 60 days. Members see every one, with its score and cash runway, sorted by date.Get in free →
Quality Score

Why DMRA scores 2

Below AverageTrending down, 3 of 13 possible checks firingWhat the Quality Score means

Poor is below 0. Average starts at 6, Above Average at 11, Excellent at 15, and Exceptional at 20.

  • +3Momentum traits 3 firing right now, of 13 possible, one point each
  • +3Insider trades Jennifer Jarrett (Director, President and CEO) bought $253K on Sep 25, and 1 more filing
  • Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
  • Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
  • Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Long-term trend, Run-up, Size, Growth, Dilution, Persistence, and News.

What every line is worth, and the reason behind it, on DMRA and every other stock.Get in free →

Price, score, traits, and the industry rank are from a snapshot taken at 9:14 AM ET, at least 15 minutes behind. How we rank stocks.

What's next

Expected to report Thu Nov 5, after the close

What would turn DMRA's score around: 6 things, for members

Alert me when DMRA's Quality Score turns up

No sign-up. No card. One tap and you're in.

For members

Here is what members see.

Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.

A member's scanner card for AMD: the Quality Score badge, the rank in the scan and in its industry, the momentum bar, three plain lines on its strength, notable holders, and early signs, and pills for size, volume, RSI, and short interest
A card on the scanner, shown on AMD
A member's stock page for AMD: the price, the Quality Score, the rank, the traits firing, relative strength, and the chart
A stock page
The scanner a member sees: every stock as a card with its Quality Score, rank, and momentum bar, the watchlist, and the day's top gainers
The scanner
The 14 checks

DMRA has 3 of a possible 13 checks firing

14 checks. Two are opposites (heavy volume and quiet volume), so at most 13 are on at once. One per group is shown here.

Trend1 of 5 shown
MA FAN21 EMAW.EMAHH/HL52W HI

Averages stacked in order, price near its high.

Volume1 of 3 shown
VOLVDUU/D VOL

Heavy volume on the run, quiet volume at rest.

Tight range1 of 3 shown
ATR SQZSQUEEZENR7

The daily range is tight against its own recent history.

Buying1 of 3 shown
OBV+CLOSE HISPRING

Closes near the high, and buyers step in on dips.

The other 10 checks on DMRA, and all 14 on every stock.Get in free →
Its industry

How DMRA ranks in Biotech

DMRA is #91 of 260 by Quality Score. The top three are shown with their scores, and the rest by name.

More in Biotech, on the Healthcare page →

Earnings

When does DMRA report, and what happens after?

Expected to report Thu Nov 5, after the close (in 38 days). Not yet confirmed by the company.

Filings

Who is trading DMRA

Insiders

One insider bought $253K across 1 filing, and one insider sold $7K across 1 filing, in the last 6 months. The newest:

BuyJennifer Jarrett$253KDirector, President and CEOat $20.23 on Sep 25, filed today
All 2 insider filings on DMRA from the last six months, for members.Get in free →

An insider has two business days to file a Form 4, so the trade is already days old when it becomes public. Shown as filed, with no delay.

See CEOs buying their own stock across the market →

The company

About Damora Therapeutics

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

7 employeesWaltham, MAdamoratx.com

For members

Every line of the score, on every stock.

  • Real-time prices, no delay
  • Every line of DMRA's score, with the points and the reason
  • All 14 checks on DMRA and on all 2,951 stocks
  • Every stock ranked, with the chart
  • Every filing, and optional alerts on DMRA
BreakawaynowJennifer Jarrett bought DMRA$253K at $20.23, filed Sep 28

What a filing on DMRA would have sent. Alerts are optional.

See all 14 checks on DMRANo sign-up. No card. One tap and you're in.
Questions

Straight answers.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Where does the data come from?

Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week traits rest on real history. Options flow is not part of the product.

What does it cost?

One plan with everything in it: $29 a month, $69 for three months, or $249 a year. You pick the billing period when the trial ends, and payments go through Stripe, so Breakaway never sees your card.

Is this investment advice?

No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.

The price, the score, the traits, and the industry rank on this page are delayed at least 15 minutes. Filings are shown as filed, because a disclosure is already days or weeks old when it becomes public. Earnings dates and past reactions are settled sessions.